Early breast cancer: How long should tamoxifen continue?

Early breast cancer: How long should tamoxifen continue?

Show other versions (1)

Bibliographic Details
Main Authors:	Davies, C, Monaghan, H, Peto, R
Format:	Journal article
Published:	1998

Similar Items

Early breast cancer: How long should tamoxifen continue?
by: Davies, C, et al.
Published: (1999)

Tamoxifen therapy for patients with breast cancer - Authors' reply.
by: Davies, C, et al.
Published: (2013)

Tamoxifen for early breast cancer: better late than never.
by: Gray, R, et al.
Published: (2000)

WITHDRAWN: Tamoxifen for early breast cancer.
by: Clarke, M
Published: (2008)

Early and late tamoxifen resistance in breast cancer
by: Abu Rabi Z., et al.
Published: (2010-01-01)

Variation in use of adjuvant tamoxifen.
by: Davies, C, et al.
Published: (1998)

Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen.
by: Davies, C
Published: (2004)

Tamoxifen for early breast cancer: an overview of the randomised trials
by: Early Breast Cancer Trialists' Collaborative Group
Published: (1998)

EFFECTS OF ADJUVANT TAMOXIFEN AND OF CYTOTOXIC THERAPY ON MORTALITY IN EARLY BREAST-CANCER - AN OVERVIEW OF 61 RANDOMIZED TRIALS AMONG 28,896 WOMEN
by: Peto, R
Published: (1989)

[Duration of adjuvant treatment with tamoxifen in patients with resectable breast cancer]
by: Davies, C, et al.
Published: (1998)

Assessing Predictors of Tamoxifen Nonadherence in Patients with Early Breast Cancer
by: Montagna E, et al.
Published: (2021-09-01)

Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine
by: Yuntao Wang MS, et al.
Published: (2021-03-01)

How long should the COVID-19 lockdown continue?
by: Jonathan Caulkins, et al.
Published: (2020-01-01)

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer
by: Early Breast Cancer Trialists' Collaborative Group
Published: (1988)

Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer
by: Jaime D. Lewis, et al.
Published: (2014-11-01)

Extended adjuvant tamoxifen for early breast cancer: a meta-analysis.
by: Mustafa Al-Mubarak, et al.
Published: (2014-01-01)

Five years of tamoxifen--or more?
by: Peto, R
Published: (1996)

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
by: Davies, C, et al.
Published: (2013)

10 vs 5 years of adjuvant tamoxifen: exclusion of 1/402 centres in ATLAS
by: Davies, C, et al.
Published: (2017)

The benefits and costs of tamoxifen for breast cancer prevention
by: Simon D. Eckermann, et al.
Published: (2003-02-01)

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
by: Dowsett, M, et al.
Published: (2009)

Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells
by: Seo Yun Moon, et al.
Published: (2021-08-01)

Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse
by: A. B. Sanchez-Spitman, et al.
Published: (2021-01-01)

The use of tamoxifen in the treatment and prevention of breast cancer
by: Magdalena Hołowczuk, et al.
Published: (2019-06-01)

The use of tamoxifen in the treatment and prevention of breast cancer
by: Magdalena Hołowczuk, et al.
Published: (2019-06-01)

A Reconsideration Of Tamoxifen Use for Breast Cancer
by: Peng-Hui Wang, et al.
Published: (2007-06-01)

Tamoxifen for women at high risk of breast cancer
by: Nazarali SA, et al.
Published: (2014-02-01)

Tamoxifen in breast conservation therapy.
by: Lee, K, et al.
Published: (1995)

From Micro to Long: Non-Coding RNAs in Tamoxifen Resistance of Breast Cancer Cells
by: Jéssica Fernanda Barazetti, et al.
Published: (2021-07-01)

Risk of fatty liver after long-term use of tamoxifen in patients with breast cancer.
by: Jeong-Ju Yoo, et al.
Published: (2020-01-01)

Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.
by: Gelber, R, et al.
Published: (1996)

Aromatase Inhibitors (AIs) Versus Not (Placebo/Observation) as Late Extended Adjuvant Therapy for Postmenopausal Women with Early Stage Breast Cancer (BC): Overviews of Randomized Trials of AIs after similar to 5 Years of Tamoxifen
by: Goss, P, et al.
Published: (2009)

How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?
by: Katherine D. Crew, et al.
Published: (2017-05-01)

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
by: Davies, C, et al.
Published: (2013)

Association of tamoxifen resistance and lipid reprogramming in breast cancer
by: Susanne Hultsch, et al.
Published: (2018-08-01)

Progress in the Understanding of the Mechanism of Tamoxifen Resistance in Breast Cancer
by: Jingwei Yao, et al.
Published: (2020-12-01)

Tamoxifen-associated vasculitis in a breast cancer patient
by: Vargas-Viveros Pablo, et al.
Published: (2007-01-01)

Adjuvant CMF and tamoxifen in the elderly breast cancer patients
by: Vrbavac Milenko, et al.
Published: (2002-01-01)

The effects of tamoxifen on homocysteine levels in breast cancer patients
by: Eroğlu Aydan, et al.
Published: (2009-12-01)

Tamoxifen treatment adherence assessment by women with breast cancer
by: Caroline Oliveira Rangel, et al.
Published: (2020-01-01)